Therapeutic Indications and Benefits

Vigantol is an oral vitamin D3 supplement containing colecalciferol. It is primarily used to manage conditions related to vitamin D deficiency and to support calcium metabolism within the body.

Prevention and Treatment of Vitamin D Deficiency

The primary application of Vigantol is the prevention of vitamin D deficiency in children and adults. It is frequently indicated for individuals with an identified risk of deficiency due to limited sunlight exposure, malabsorption syndromes, or specific dietary restrictions. In cases where a deficiency has already been diagnosed, it is used as a treatment to restore physiological levels of vitamin D.

Support for Bone Health and Osteoporosis

Vitamin D is essential for the intestinal absorption of calcium and phosphate, which are critical for the mineralization of bone tissue. Vigantol is used as a supportive treatment in the management of osteoporosis, helping to maintain bone density and reduce the risk of fractures in patients with a high risk of bone loss.

Rickets and Osteomalacia

Vigantol is used in the prevention and treatment of rickets in infants and children, a condition characterized by the softening and weakening of bones. In adults, it is used to treat osteomalacia, the adult form of bone softening often caused by severe, long-term vitamin D deficiency.

Maintenance of Hypoparathyroidism

In certain cases, Vigantol is used in the management of hypoparathyroidism. By supplementing vitamin D levels, it helps regulate serum calcium levels in patients whose parathyroid glands do not produce sufficient hormone to maintain mineral balance independently.

Benefits for Neonatal Health

For newborns and infants, particularly those who are breastfed or born prematurely, vitamin D supplementation is often necessary to ensure healthy skeletal development and to prevent early-onset deficiency during periods of rapid growth.

Regulatory References

1. NIH MedlinePlus Medical Encyclopedia

The eligibility profile for Vigantol (Dihydrotachysterol) is strictly determined by regulatory documents, focusing on a patient's existing metabolic status and reproductive state.

Populations for Whom Use is Contraindicated

The medicine is contraindicated (must not be used) in populations with preexisting conditions of excess Vitamin D or calcium, as explicitly defined in regulatory labeling:

• Patients with Hypercalcaemia (abnormally high blood calcium levels).
• Patients with Hypervitaminosis D (excessive Vitamin D levels).
• Individuals with an abnormal sensitivity to the effects of Vitamin D.
• Nursing Mothers (Breastfeeding Women).

Age and Organ Function Eligibility

Age-Related Eligibility: Use is established and documented for the pediatric population, including neonates, infants, and children, for specified conditions.

Organ Function: Use is established in patients with renal impairment or renal osteodystrophy. The drug is noted as often preferred in this population as it is active without needing final hydroxylation in the kidney.

Restricted and Conditional Use

• Pregnancy: Use is restricted and permitted only when the potential clinical benefit is determined to justify the potential risk to the fetus.
• Comorbidities: The regulatory labeling advises special caution for use in patients with Sarcoidosis or a history of renal stones.

Interactions with other medicines and products

The official regulatory profile for Dihydrotachysterol (Vigantol) establishes specific restrictions and necessary constraints on co-administration with other medicines and substances.

Formal Restrictions and Contraindications

Co-administration with Calcium Supplements and other Vitamin D Analogues (such as Calcitriol or Cholecalciferol) is formally restricted due to the potential for significant additive hypercalcemia.

Pharmacodynamic and Exposure Interactions

The hypercalcemic effect of Dihydrotachysterol enhances the cardiotoxicity of Cardiac Glycosides (e.g., Digoxin), increasing the risk of ventricular arrhythmias. Co-administration with Thiazide Diuretics (e.g., Chlorothiazide) may also increase the severity of hypercalcemia, which is a documented pharmacodynamic interaction.

Substances that interfere with drug exposure, such as Bile Acid Sequestrants (e.g., Cholestyramine), may decrease the serum concentration of Vigantol by reducing its absorption. Conversely, enzyme-inducing Anticonvulsants (e.g., Phenytoin, Phenobarbital) or drugs like Rifampicin may reduce the effectiveness of Dihydrotachysterol by accelerating its metabolic clearance. Corticosteroids may also decrease its therapeutic efficacy.

Dietary and Population Constraints

Consumption of a diet high in Calcium, Phosphate, or Vitamin D requires consideration due to the risk of additive toxicity. Grapefruit juice is documented to potentially alter the drug’s blood levels. The absorption of the fat-soluble medicine may be decreased in patients with Hepatic and/or Biliary Dysfunction.

Vigantol, which contains cholecalciferol (Vitamin D3), functions as an inactive secosteroid prohormone. Systemic circulation delivers cholecalciferol, which is first metabolized in the liver via 25-hydroxylase enzymes (primarily CYP2R1) to the circulating prehormone 25-hydroxyvitamin D (25(OH)D). This intermediate is subsequently hydroxylated in the kidney by the mitochondrial 1alpha-hydroxylase (CYP27B1) to form the biologically active hormone, 1,25-dihydroxyvitamin D (1,25(OH)2D, calcitriol). Calcitriol acts as a nuclear agonist for the ubiquitous Vitamin D Receptor (VDR), a ligand-activated transcription factor. Upon binding, the 1,25(OH)2D-VDR complex heterodimerizes with the Retinoid X Receptor (RXR), translocates to the nucleus, and binds to specific DNA sequences termed Vitamin D Response Elements (VDREs). This interaction modulates the transcription of target genes, including those encoding calcium-binding proteins (e.g., calbindin) and transient receptor potential cation channel subfamily V member 6 (TRPV6) in intestinal epithelial cells. The downstream cascade increases intestinal absorption of both calcium and phosphate. Furthermore, 1,25(OH)2D regulates renal calcium reabsorption and modulates parathyroid hormone (PTH) secretion. The system-level physiological consequence is the regulated increase and maintenance of plasma calcium and phosphate concentrations.

Vigantol, which contains Dihydrotachysterol, is officially administered exclusively by the oral route. The medicine is available in multiple dosage forms, including oral tablets (such as 0.125 mg to 0.4 mg strengths) and an oral solution in drops (e.g., 250 micrograms/ml), which is intended for accurate measurement of the prescribed dose. The overall administration protocol is structured into distinct, sequential phases to achieve and sustain the intended mineral balance according to label specifications.

The administration pattern is fundamentally biphasic, beginning with an initial treatment phase that employs a relatively higher daily dose (for adults, typically in the range of 0.8 mg to 2.4 mg) administered for a short duration, usually over a few days. This is followed by a maintenance phase, which utilizes a lower, sustained daily amount, often ranging from 0.2 mg to 1.0 mg. The usual frequency of use is once daily, though certain official maintenance regimens permit dosing on alternate days or as an intermittent weekly total.

A crucial procedural requirement is that the dose must be highly individualized for each patient, due to the compound's narrow therapeutic window. Treatment is tightly controlled by the frequent determination of serum calcium levels, which must be measured one to two times per week during the initial adjustment period and approximately monthly once the levels stabilize. The specific dosage is then titrated (adjusted) over periods of four to eight weeks until the required serum calcium target is achieved, ensuring the use aligns precisely with official procedural guidance.

Research Evidence / Overview of Studies for Vigantol

Evidence for use in Managing Hypoparathyroidism

Vigantol (Dihydrotachysterol) was included in research exploring the chronic mineral imbalance known as hypoparathyroidism, a condition leading to low blood calcium. The research landscape includes older comparative clinical trials, where it was studied alongside other types of active Vitamin D analogues or established conventional therapies. Importantly, there are also long-term observational cohort studies that have followed patients over many years.

These studies monitored outcomes related to systemic or functional imbalance, specifically looking at the stabilization of key biomarkers like serum calcium and phosphate levels. Research monitored outcomes related to neuromuscular hyperexcitability, such as tetany. The long-term observational data show patterns related to rates of renal complications, including kidney stone formation, in observed populations receiving this type of conventional therapy. Studies report how symptoms evolved in the observed populations and contribute to the broader evidence landscape for this type of mineral management.

Evidence for use in Managing Pseudohypoparathyroidism

For the rare condition known as pseudohypoparathyroidism, the available research is more limited. The evidence base primarily consists of historical clinical experience summaries, small case series, and older studies. In these settings, Dihydrotachysterol was observed in patients with this condition where symptoms may vary in intensity.

The research explored whether consistent and stable calcium levels were observed as an outcome related to systemic or functional imbalance. Case reports described patterns observed in the studies regarding the severe mineral imbalance characteristic of the condition. Due to the rarity of this condition, evidence is limited and largely historical.

What is Still Uncertain About the Research

A major gap is the lack of comparative evidence from recent, large-scale clinical trials that directly compare Dihydrotachysterol to the newest therapeutic options for chronic hypoparathyroidism. The findings related to long-term complication rates, while extensively documented in observational studies, are still emerging from controlled settings. Furthermore, follow-up durations were limited in many short-term trials, and the evidence quality varies across studies when looking at different indications.

Key Studies & References

1. Vitamin D and Bone Health: A Systematic Review for Primary Care
2. Mineral Metabolism and Bone Disease (Reference for Pharmacological Class and Use in Rickets/Osteomalacia)

Common questions about Vigantol (FAQ)

Q: How is Vigantol different from standard over-the-counter Vitamin D supplements?

Vigantol's active ingredient, Dihydrotachysterol, is described in official sources as a synthetic form of Vitamin D. It is chemically distinct from Vitamin D2 and D3, which are typically found in over-the-counter supplements. A key difference is how it is activated in the body, which makes it a pharmacologically distinct compound for mineral management.

Q: Why do doctors prescribe Vigantol in drop form?

According to official product information, Dihydrotachysterol is supplied as an oral solution in a concentration known as Intensol, often with a calibrated dropper. This drop format is used specifically to allow for the highly individualized and precise dosage adjustments that are required for this particular medication.

Q: How long should Vigantol treatment last?

The total duration of treatment is determined by the prescribing doctor and is often necessary for chronic conditions like hypoparathyroidism. Official dosage regimens are typically biphasic, starting with an initial higher dose for a short period, followed by a daily maintenance dose for a sustained time.

Q: Can I take Vigantol with dairy products?

Official guidance indicates that Dihydrotachysterol can be taken before or after meals. However, official guidance highlights the need for adjustment of dietary intake of foods containing high levels of calcium and phosphate while on treatment, as these substances can affect the therapeutic balance.

Q: Does Vigantol affect liver function?

The official profile highlights a disease interaction with hepatobiliary dysfunction (problems with the liver or bile ducts). Regulatory documents highlight the need for closer observation in patients with pre-existing liver conditions, as there is limited regulatory data regarding dose adjustments in this population.

Q: Are the drops and capsules of Vigantol medically equivalent?

Both the oral solution (drops) and tablets are available by prescription in various equivalent concentrations. The choice of form is often related to the required precision of the dose. The oral solution is particularly useful for precise adjustments to accommodate the individualized dosing approach.

Q: Is Vigantol effective for low bone density?

Official documents state that Dihydrotachysterol is indicated for managing abnormal mineral balance associated with conditions like hypoparathyroidism. The medication is also indicated for the treatment of osteoporosis when it is used as part of a regimen that includes calcium supplementation.

Q: How long does it typically take to see results after starting Vigantol?

Studies and official information on Dihydrotachysterol report that the onset of action, or the time it takes for the drug to begin affecting the body's mineral levels, has been observed to start within 4 to 7 days after initiating treatment.

Q: Can Vigantol cause weight gain or loss?

The official regulatory profile for Dihydrotachysterol includes weight loss as a reported potential adverse effect. This information is found in the medication's adverse reaction documents.

Q: Does Vigantol need to be taken at a specific time of day?

Labeling information indicates the drug may be administered before or after meals once daily. No specific time of day is mandated in the official instructions for taking Dihydrotachysterol.

Q: Is Vigantol safe for elderly patients?

While the medicine is used in the elderly population, official guidance suggests that dose selection should be conducted with caution. Official guidance emphasizes starting at the low end of the dosing range due to the greater natural frequency of decreased kidney, liver, or heart function observed in older patients.

Q: Does Vigantol contain any sugar or allergens?

The tablet formulations are known to contain inactive ingredients, including sucrose (a sugar) and lactose. Furthermore, the drug is contraindicated in patients who have an abnormal sensitivity to the effects of vitamin D.

Q: What are the common symptoms of Vitamin D deficiency that Vigantol treats?

The medication is specifically prescribed to manage conditions resulting from calcium and Vitamin D imbalances. These conditions include hypoparathyroidism, hypocalcemia (low blood calcium), rickets (in children), and osteomalacia (in adults).

Q: Does Vigantol interact with antacids?

Official information documents potential interactions with certain over-the-counter products. The guidance indicates that certain antacids containing magnesium or calcium must be avoided due to the potential for interaction with Dihydrotachysterol.

How to Store and Dispose of Vigantol

Official regulatory guidelines require specific conditions to maintain the stability and safety of Vigantol (cholecalciferol).

Storage Requirements

Disposal Instructions

Dispose of unused or expired Vigantol preferably through a drug take-back program or an authorized collection site. Do not flush medicine down the toilet or pour it down a drain unless specifically instructed to do so.

If take-back options are unavailable, mix the medicine with an unappealing substance (like dirt or coffee grounds), place the mixture into a sealed container (e.g., a plastic bag), and discard it in the household trash. This method is specified to prevent accidental poisoning and environmental contamination.